STK11 and non-small cell lung carcinoma: To challenge this conclusion, recent data from a subgroup analysis from the phase 3 KEYNOTE-189 study showed that some patients with LKB1-mutated NSCLC can achieve clinical benefit from adding immunotherapy to first-line chemotherapy [64].